PPARgamma as a potential therapeutic target in pulmonary hypertension.
PPARgamma as a potential therapeutic target in pulmonary hypertension.
复制标题
DOI：
10.1177/1753465809369619
复制
发表时间：
2010-06
影响因子：
4.3
通讯作者：
Hart CM
中科院分区：
文献类型：
--
作者：
Sutliff RL;Kang BY;Hart CM
肺动脉高压（PH）是一种进行性肺循环疾病，与显著的发病率和死亡率相关。PH的病理生物学涉及一系列复杂的紊乱，导致内皮功能障碍、血管收缩和肺血管壁细胞的异常增殖，从而导致肺血管阻力和压力增加。最近的证据表明配体激活的转录因子，过氧化物酶体增殖物激活受体γ本文综述了过氧化物酶体增殖物激活受体γ（PPARγ）的生物学特性和新近发现的证据，这些证据表明，激活这种受体的治疗方法可能为PH的治疗提供新的途径。对PPARγ配体在PH中治疗作用的潜在机制的深入了解。
Pulmonary hypertension (PH) is a progressive disorder of the pulmonary circulation associated with significant morbidity and mortality. The pathobiology of PH involves a complex series of derangements causing endothelial dysfunction, vasoconstriction and abnormal proliferation of pulmonary vascular wall cells that lead to increases in pulmonary vascular resistance and pressure. Recent evidence indicates that the ligand-activated transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) can have a favorable impact on a variety of pathways involved in the pathogenesis of PH. This review summarizes PPARγ biology and the emerging evidence that therapies designed to activate this receptor may provide novel approaches to the treatment of PH. Mediators of PH that are regulated by PPARγ are reviewed to provide insights into potential mechanisms underlying therapeutic effects of PPARγ ligands in PH.